Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O-6-methylguanine-DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, and predictive impact of MGMT inactivation in two multicenter cohorts. MGMT inactivation was assessed through PCR and immunohistochemistry (IHC) in an Italian cohort; the results were then externally validated using RNA sequencing (RNA-seq) data from the BTC subcohort of the Molecularly Aided Stratification for Tumor Eradication Research (MASTER) precision oncology program of the National Center for Tumor Diseases Heidelberg and the German Cancer Consortium. Among 164 Italian cases, 18% presented MGMT promoter hypermethylation (> 14%) and 73% had negative MGMT protein expression. Both were associated with worse overall survival (OS; HR 2.31; P < 0.001 and HR 1.99, P = 0.012, respectively). In the MASTER cohort, patients with lower MGMT mRNA expression showed significantly poorer OS (median OS [mOS] 20.4 vs 31.7 months, unadjusted HR 1.89; P = 0.043). Our results suggest that MGMT inactivation is a frequent epigenetic alteration in BTC, with a significant prognostic impact, and provide the rationale to explore DNA-damaging agents in MGMT-inactivated BTCs.

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers / M. Niger, F. Nichetti, A. Casadei-Gardini, F. Morano, C. Pircher, E. Tamborini, F. Perrone, M. Canale, D.B. Lipka, A. Vingiani, L. Agnelli, A. Dobberkau, J. Hüllein, F. Korell, C.E. Heilig, S. Pusceddu, F. Corti, M. Droz, P. Ulivi, M. Prisciandaro, M. Antista, M. Bini, L. Cattaneo, M. Milione, H. Glimm, B.C. Köhler, G. Pruneri, D. Hübschmann, S. Fröhling, V. Mazzaferro, F. Pietrantonio, M. Di Bartolomeo, F. de Braud. - In: MOLECULAR ONCOLOGY. - ISSN 1574-7891. - 16:14(2022), pp. 2733-2746. [10.1002/1878-0261.13256]

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers

M. Niger;F. Nichetti;C. Pircher;A. Vingiani;L. Agnelli;S. Pusceddu;F. Corti;M. Prisciandaro;M. Bini;G. Pruneri;V. Mazzaferro;F. Pietrantonio;F. de Braud
2022

Abstract

Biliary tract cancers (BTCs) have poor prognosis and limited therapeutic options. The impact of O-6-methylguanine-DNA methyltransferase (MGMT) inactivation in advanced BTC patients is not established. We investigated the prevalence, prognostic, and predictive impact of MGMT inactivation in two multicenter cohorts. MGMT inactivation was assessed through PCR and immunohistochemistry (IHC) in an Italian cohort; the results were then externally validated using RNA sequencing (RNA-seq) data from the BTC subcohort of the Molecularly Aided Stratification for Tumor Eradication Research (MASTER) precision oncology program of the National Center for Tumor Diseases Heidelberg and the German Cancer Consortium. Among 164 Italian cases, 18% presented MGMT promoter hypermethylation (> 14%) and 73% had negative MGMT protein expression. Both were associated with worse overall survival (OS; HR 2.31; P < 0.001 and HR 1.99, P = 0.012, respectively). In the MASTER cohort, patients with lower MGMT mRNA expression showed significantly poorer OS (median OS [mOS] 20.4 vs 31.7 months, unadjusted HR 1.89; P = 0.043). Our results suggest that MGMT inactivation is a frequent epigenetic alteration in BTC, with a significant prognostic impact, and provide the rationale to explore DNA-damaging agents in MGMT-inactivated BTCs.
MGMT; biliary tract cancer; biomarker; cholangiocarcinoma; molecular profiling; temozolomide; Biomarkers; DNA Modification Methylases; DNA Repair Enzymes; Humans; O(6)-Methylguanine-DNA Methyltransferase; Precision Medicine; Tumor Suppressor Proteins; Bile Duct Neoplasms; Biliary Tract Neoplasms
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Molecular Oncology - 2022 - Niger - MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 511.12 kB
Formato Adobe PDF
511.12 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/937309
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact